News & Media

Recent updates from Arcutis.

July 23, 2024

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over

July 22, 2024

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

July 9, 2024 Featured

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age

July 9, 2024

Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis

July 3, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 10, 2024

Arcutis Announces New Long-Term Data of Roflumilast Cream 0.15% for the Treatment of Mild to Moderate Atopic Dermatitis (AD) in Adults and Children Down to Age Six Presented at Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 5, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 5, 2024

Arcutis Announces Multiple Abstracts, Including Oral Presentation, Accepted at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference

June 3, 2024

Arcutis to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

May 14, 2024

Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology

May 3, 2024

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Media Resources

Corporate Fact Sheet

Uncovering Psoriasis

Journal of the American Medical Association Roflumilast Cream 0.3% Result

Media Contact

Amanda Sheldon

805.418.5006
media@arcutis.com

Meaningful innovation at a glance.

Download our corporate fact sheet.

Download